Literature DB >> 27373368

Continued Role of Splenectomy in the Management of Patients With Myelofibrosis.

Daniel Aruch1, Myron Schwartz2, John Mascarenhas1, Marina Kremyanskaya1, Carrie Newsom1, Ronald Hoffman3.   

Abstract

Entities:  

Keywords:  Cytopenias; JAK2 inhibition; Myeloproliferative neoplasms; Ruxolitinib; Splenomegaly

Mesh：

Year:  2016        PMID： 27373368     DOI： 10.1016/j.clml.2016.06.007

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  4 in total

1.  Genomic characterization of spleens in patients with myelofibrosis.

Authors:  Eran Zimran; Joseph Tripodi; Raajit Rampal; Franck Rappoport; Sharon Zirkiev; Ronald Hoffman; Vesna Najfeld
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

2.  Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.

Authors:  Xiaoli Wang; Cing Siang Hu; Bruce Petersen; Jiajing Qiu; Fei Ye; Jane Houldsworth; Kevin Eng; Fei Huang; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-09-25

Review 3.  Modern management of splenomegaly in patients with myelofibrosis.

Authors:  Douglas Tremblay; Myron Schwartz; Richard Bakst; Rahul Patel; Thomas Schiano; Marina Kremyanskaya; Ronald Hoffman; John Mascarenhas
Journal:  Ann Hematol       Date:  2020-05-17       Impact factor: 3.673

4.  Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis.

Authors:  Marco Casaccia; Rosario Fornaro; Marco Frascio; Denise Palombo; Cesare Stabilini; Emma Firpo; Ezio Gianetta
Journal:  Int J Surg Case Rep       Date:  2017-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.